ArticleBMC nephrology2026
Management strategies for post-transplant IgA nephropathy in kidney transplant recipients: a scoping review.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPost-transplant Immunoglobulin A Nephropathy (IgAN) is an important cause of premature graft loss. Management strategies are often extrapolated from native IgAN, with available evidence limited to heterogeneous, predominantly small retrospective studies.
objectivesTo characterise diagnostic criteria, map management strategies, and summarise associated clinical outcomes in post-transplant IgAN.
methodsA literature search was performed in MEDLINE, Embase, Web of Science, and Scopus (1st January 2000-11th December 2025) following Joanna Briggs Institute (JBI) and PRISMA-ScR guidelines. English-language studies of adult kidney transplant recipients with biopsy-proven post-transplant IgAN and documented management strategies were included. Data on study design, cohorts, diagnostic criteria, interventions, and outcomes were charted and narratively described.
resultsTwenty-seven studies met the inclusion criteria. Most were single-centre retrospective cohorts. Diagnostic criteria varied, but typically histological evidence of IgA deposition alone was sufficient. IgAN was often clinically relevant, with proteinuria > 1 g/day frequently reported. Reported treatments included renin-angiotensin-aldosterone system (RAAS)-blockade, immunosuppression adjustment, rituximab, tonsillectomy and pulsed corticosteroids. Several small case series explored emerging therapies (iptacopan, budesonide, telitacicept). Study heterogeneity precluded quantitative data synthesis.
conclusionsRAAS-blockade was the most commonly used intervention and was associated with benefit in several studies. Tonsillectomy was associated with improved outcomes but reported only in Japanese cohorts. Other interventions (rituximab, pulsed steroids, emerging therapies) warrant prospective clinical trials. Amid evolving paradigms in native IgAN management, this review highlights heterogeneity in diagnostic criteria, outcome reporting, and interventions for the management of post-transplant IgAN. Robust prospective, multicentre studies are urgently required to define optimal management in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.